Navigation Links
Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/6/2009

1,791 1,767 Commitments and contingencies Stockholders' equity: Preferred stock, $.001 par value, 10,000,000 shares authorized at June 30, 2009 and December 31, 2008; no shares issued and outstanding at June 30, 2009 and December 31, 2008 - - Common stock, $.001 par value, 100,000,000 shares authorized at June 30, 2009 and December 31, 2008; 34,661,541 and 34,433,322 shares issued and outstanding at June 30, 2009 and December 31, 2008, respectively 35 34 Additional paid-in capital 256,677 253,782 Accumulated other comprehensive income 44 153 Deficit accumulated during the development stage (237,284) (200,175) -------- -------- Total stockholders' equity 19,472 53,794 ------ ------ Total liabilities and stockholders' equity $51,305 $91,908 ======= =======
                              Orexigen Therapeutics, Inc.
                             (a development stage company)
                                Statements of Operations
                        (In thousands, except per share amounts)
                                      (Unaudited)

                                                                Period from
                        Three Months Ended   Six Months Ended  September 12,
                             June 30,             June 30,         2002
                             --------             --------    (Inception) to
                           2009     2008        2009    
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
2. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
3. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
6. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
7. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6
9. Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics: From Concept to Implementation Conference
10. United Therapeutics Corporation Reports Second Quarter 2009 Financial Results
11. Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... School of Medicine in St. Louis helps explain why ... are more harmful than similar tumors in females. For ... diagnosed twice as often in males, who suffer greater ... long. , The researchers found that retinoblastoma protein (RB), ... less active in male brain cells than in female ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... the wake of the 2012 Rejuvenate and ABG ... forward in New Jersey’s Bergen County Superior Court, ... in the proceeding, the Court has issued ... governing any and all hard copy and electronic ...
(Date:8/1/2014)... As it continues to investigate morcellator ... allegedly experienced the spread of uterine cancers due to ... Liebhard LLP notes the growing reaction to Johnson & ... marketed by its Ethicon, Inc. unit from the market. ... some critics of the company said they were “pleasantly ...
(Date:8/1/2014)... and transgender individuals who want to conceive a child ... heterosexual and cisgendered peers, such as reduced fertility, but ... legal challenges to become parents. A comprehensive review of ... presented in the article " LGBT Assisted Reproduction: Current ... LGBT Health , a peer-reviewed journal from Mary ...
(Date:8/1/2014)... 01, 2014 Market Publishers Ltd ... have been added to its catalogue. , ... Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), ... industry drivers include, among others, increasing ageing population, ... In 2015, the pharma market in India is ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3
... Mozes HealthDay Reporter , WEDNESDAY, June 30 (HealthDay ... test and a brain scan may best predict the likelihood ... to develop Alzheimer,s disease. Mild cognitive impairment (MCI), is ... language or another mental function severe enough to be noticeable ...
... By Jenifer Goodwin HealthDay Reporter , ... Parkinson,s disease patients who received fetal cell transplants in ... they can prevent the troublesome side effect. The ... they said. "These findings lend much optimism to ...
... the Stanford University School of Medicine have identified a ... because the existence of such a cell in the ... It may also explain why current immunotherapies are largely ... "These cells lack the traditional melanoma cell surface ...
... Smoking, an established risk factor for colon cancer, may induce ... in the development of colon cancer, according to an online ... National Cancer Institute. Cigarette smoking is a ... that people who currently smoke or smoked in the past ...
... led by a team from the University at Buffalo ... randomized double-blinded study to test the safety and efficacy ... on the symptoms and progression of Multiple Sclerosis (MS). ... venous insufficiency (CCSVI) with MS. , In a series ...
... a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory ... than a drug already available for treating cancer. In a ... the Journal of Leukocyte Biology ( http://www.jleukbio.org ), ... to treat cancers that affect white blood cells, induces cell ...
Cached Medicine News:Health News:Predicting Alzheimer's Risk in Patients With Cognitive Problems 2Health News:Predicting Alzheimer's Risk in Patients With Cognitive Problems 3Health News:Predicting Alzheimer's Risk in Patients With Cognitive Problems 4Health News: Parkinson's Transplant Mystery Solved, Researchers Say 2Health News: Parkinson's Transplant Mystery Solved, Researchers Say 3Health News:Melanoma-initiating cell identified by Stanford scientists 2Health News:Melanoma-initiating cell identified by Stanford scientists 3Health News:Melanoma-initiating cell identified by Stanford scientists 4Health News:Smoking-related colorectal cancer in older women is associated with molecularly defined DNA changes 2Health News:University at Buffalo launches clinical trial of new multiple sclerosis treatment 2Health News:University at Buffalo launches clinical trial of new multiple sclerosis treatment 3Health News:Cancer drug shows promise for treating a wide range of inflammatory diseases 2
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health ... to speak a second language. Clinical efficacy is no ... established under the ACA like PCORI are directing roughly ... variety of new entities and environments, the federal healthcare ... the new language of outcomes and managed markets to ...
(Date:8/1/2014)... Aug. 1, 2014  VanDeMark Chemical Inc., ... manufacturer of phosgene and phosgene derivatives in ... it has acquired Framochem Kft, a leading European-based ... Hungary . The purchase unites ... one of the world,s largest, independent manufacturers of ...
(Date:8/1/2014)... 2014 Research and Markets ... Medical Biosensors Market 2014-2018" report to their ... Medical biosensors are used to analyze ... These biosensors monitor health status, disease betterment, and ... They are cost-effective and user-friendly devices. Also, they ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2
... 19, 2012  The Specialty Photonics Division of OFS ... optical fiber, cable, and assemblies for medical device ... "Optical fibers with polyimide coatings for medical applications" ... will present on Sunday, January 22nd at 12:10 ...
... 19, 2012 RESMED INC. (NYSE: RMD ), announced ... results for the second quarter and six months of fiscal year ... will be issued after 1:00 p.m. Pacific Time and the company ... market trends, and future outlook. Please note only the "outside ...
Cached Medicine Technology:OFS to Present Paper on Optical Fibers with Polyimide Coatings for Medical Applications 2ResMed Announces Change to Outside US Dial-in Number for Conference Call and Webcast to Discuss Second Quarter 2012 Results 2
... a two-piece Titanium (Ti-6Al-4V) screw offered in ... variety of lengths. The two pieces are ... packaged. A single instrument set contains all ... both Standard and Mini Kompressor Compression Screws. ...
... Avanta Total Wrist is designed ... in patients suffering from rheumatoid, ... The implant is designed as ... bone resection and aiding in ...
... Within the last decade KMI® revolutionized the ... the Universal Total Wrist System. We're at ... next generation product, the Universal2. Like the ... the way patients live with debilitating arthritis. ...
... NeedlePunch is a simple, effective instrument to grasp ... FiberWire stitch and loop. The grasping function of ... soft tissue and precisely place a stitch up ... the tissue, all in one quick step. The ...
Medicine Products: